These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 8750009)

  • 1. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
    Bagshawe KD
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1421-31. PubMed ID: 17069527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
    Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
    Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
    Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
    Greco O; Dachs GU
    J Cell Physiol; 2001 Apr; 187(1):22-36. PubMed ID: 11241346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-directed enzyme prodrug therapy using CB1954.
    Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
    Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
    Khatri A; Russell PJ
    Discov Med; 2007 Feb; 7(37):39-45. PubMed ID: 17343804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
    Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF
    Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
    Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
    Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in antibody-directed enzyme prodrug therapy.
    Sharma SK; Bagshawe KD; Begent RH
    Curr Opin Investig Drugs; 2005 Jun; 6(6):611-5. PubMed ID: 15997480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
    Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-directed enzyme prodrug therapy.
    Connors TA
    Cancer Cells; 1990 Feb; 2(2):56-7. PubMed ID: 2397145
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.
    Both GW
    Curr Opin Mol Ther; 2009 Aug; 11(4):421-32. PubMed ID: 19649987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prodrug activation enzymes in cancer gene therapy.
    Aghi M; Hochberg F; Breakefield XO
    J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.